Suggestions

Du même auteur

The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials

Archive ouverte | Péron, Julien | CCSD

International audience

Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer

Archive ouverte | Peron, Julien | CCSD

International audience. Background: Efficacy and safety are the two considerations when characterising the effects of a new therapy. We sought to apply an innovative method of assessing the benefit-risk balance usin...

Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

Archive ouverte | Bennouna, J. | CCSD

IF 11.855 . International audience

Chargement des enrichissements...